Literature DB >> 9543096

Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase.

F H de Man1, F de Beer, A van de Laarse, A H Smelt, J A Leuven, L M Havekes.   

Abstract

Lipoprotein lipase (LPL) is bound to heparan sulphate proteoglycans (HSPG) at the luminal surface of endothelium. It is the key enzyme involved in the hydrolysis of very low density lipoproteins (VLDL). Prior to lipolysis by LPL, the lipoproteins are considered to interact with vessel wall HSPG. Apolipoprotein (apo) E is thought to mediate this interaction thereby enhancing the stability of the lipoprotein-LPL complex. We hypothesize that apo E mutations may cause a diminished interaction of VLDL with HSPG leading to impaired lipolysis of VLDL by HSPG-bound LPL. In order to test this hypothesis, lipolysis experiments were performed using HSPG-bound LPL. The mean lipolysis rates of VLDL, isolated from the apo E2 (Lys146-->Gln) heterozygotes, apo E2 (Arg158-->Cys) homozygotes and apo E3-Leiden heterozygotes were 92.3 +/- 10.3 (ns), 77.3 +/- 4.2 (P < 0.05) and 76.7 +/- 10.0% (P < 0.05), respectively, of that of control VLDL (100.0 +/- 9.7%). No differences in lipolysis were observed between VLDL from controls and VLDL from the same patients if LPL in solution was used. Thus, compositional differences alone can not explain the differences in lipolysis rates observed with HSPG-bound LPL. In competition experiments, the binding efficiency to HSPG-LPL of VLDL from the apo E2 (Lys146-->Gln) heterozygotes, apo E2 (Arg158-->Cys) homozygotes and apo E3-Leiden heterozygotes was 63 (ns), 41 (P < 0.05) and 35% (P < 0.05), respectively of that of control VLDL (100%). We conclude that VLDL isolated from apo E2 homozygotes and apo E3-Leiden heterozygotes display decreased lipolysis by HSPG-bound LPL due to a defective binding of these lipoproteins to the HSPG-LPL complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543096     DOI: 10.1016/s0021-9150(97)00218-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

Review 1.  Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models.

Authors:  K W van Dijk; M H Hofker; L M Havekes
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.113

Review 2.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

Review 3.  Functional role of extracellular vesicles and lipoproteins in the tumour microenvironment.

Authors:  Julien A Menard; Myriam Cerezo-Magaña; Mattias Belting
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

4.  Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.

Authors:  Jean-Paul Pais de Barros; Aurélia Boualam; Thomas Gautier; Laure Dumont; Bruno Vergès; David Masson; Laurent Lagrost
Journal:  J Lipid Res       Date:  2009-05-05       Impact factor: 5.922

5.  ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency.

Authors:  Gery Gerritsen; Caroline C van der Hoogt; Frank G Schaap; Peter J Voshol; Kyriakos E Kypreos; Nobuyo Maeda; Albert K Groen; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk
Journal:  J Lipid Res       Date:  2008-02-10       Impact factor: 5.922

Review 6.  The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges.

Authors:  Vasileios Lazaris; Aikaterini Hatziri; Argiris Symeonidis; Kyriakos E Kypreos
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.